11 Deaths Prompt EU Review Of Novartis Drug Gilenya

Law360, New York (January 20, 2012, 2:45 PM EST) -- A European regulator said Friday it was probing Novartis AG's Gilenya after learning that 11 patients who took the multiple sclerosis drug had died, while other Gilenya users reported experiencing heart problems.

The European Medicines Agency said it was unclear whether Gilenya caused the deaths, but that it would review the benefits and risks of the drug, which is used to treat relapsing forms of multiple sclerosis.

"While the review is ongoing, the agency's committee for medicinal products for human use is advising doctors to increase...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.